Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.
about
Direct renin inhibitors for preventing the progression of diabetic kidney diseaseBlood pressure lowering efficacy of renin inhibitors for primary hypertensionCurrent Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve OutcomesReducing cardiorenal risk through combination therapy with a direct renin inhibitorAliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trialsRole of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease.Blood pressure and diabetic nephropathyAliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases.Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysisAliskiren and valsartan combination therapy for the management of hypertension.Diabetic nephropathy for the primary care provider: new understandings on early detection and treatmentImpact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.Aliskiren - an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertensionRenal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?Blood pressure lowering efficacy of renin inhibitors for primary hypertension.Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.Prevalence, Awareness, and Control of Hypertension among Diabetic Koreans.Antioxidants in kidney diseases: the impact of bardoxolone methyl.Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial.Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertensionTherapeutic approaches to slowing the progression of diabetic nephropathy - is less best?Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.Unmet needs in managing hypertension: potential role of direct renin inhibition.Application of direct renin inhibition to chronic kidney disease.Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.New class of agents for treatment of hypertension: focus on direct renin inhibition.Are we ready to use aliskiren in children?Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.New approaches to the treatment of nephropathy in diabetes.What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?The role of direct renin inhibition in clinical practice: focus on combination therapy.Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities.The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence.Renin inhibitors and cardiovascular and renal protection: an endless quest?Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases.Improving the efficacy of RAAS blockade in patients with chronic kidney disease.
P2860
Q24198989-FEFB0412-9778-4832-915B-BCBA93ADF189Q24241169-B1A0C1BB-A149-43E1-AF6E-C42D4754D17DQ26744419-535EC108-9DC9-4242-A74C-91593B765512Q26851307-25C3C738-88D3-4EFE-8293-B2DA4BEA6BEFQ28304657-2D946E8A-C102-49E7-9878-3EE8970C6F46Q30429844-D5037778-1516-4892-96B8-4FB4645389ABQ33683851-857022C5-708B-4573-9671-D16A0B5A9DA3Q33756874-1C4F5BFC-4F3B-4BE1-B821-59E1527DA8F0Q33783689-151BD511-A981-4625-A972-4ADBF72A3C6CQ34122611-375DB31A-B348-4DE3-9B86-C2E17F7B4F39Q34139070-895221A2-5FD4-4A8C-9F69-5C8CC42109C4Q34228586-2D980C7C-BF4D-458C-9EFF-AD437E1C3F47Q34237280-01A37FFE-2504-40AD-AA11-F0FA64E7DA74Q34247173-59635742-AB39-47B1-AB04-85207077DDA8Q34453476-3E3619E2-61F3-45BA-8591-995C35572E20Q34681386-D4687DC9-FAAA-4517-935E-4F1B1D4D8982Q34926825-86BF2FEB-F553-47CB-A162-78BA72C95E65Q35228179-DB30A538-DD26-4929-B3BA-DE56DAF44F1FQ36026304-DBF4BA31-3DD5-4F3F-B377-98A61139E681Q36434830-5AB4D441-756E-4F99-BD6F-BD5BE7E3BEF4Q36701736-4FE0DB0E-D895-47B2-B7DB-80792EFE4A46Q36764872-71037280-6EC0-4C40-BBF6-EA429363C1D9Q37053287-C5DCA6E2-868D-4948-94CB-AD586149CEF6Q37125703-98DE1CE4-A8CE-4D9E-94FD-CE4807F5D06AQ37449207-19B0961F-5602-462C-8F46-6F14287FCE76Q37553108-E7B67637-6751-41EC-A2D6-867CA1EC8A4DQ37750291-CE01A40D-9F04-4058-988B-603F7D2D7CC7Q37758534-DEA8A904-C962-43D5-A0AD-39264A375180Q37781702-06B55E25-0A29-4F19-AAD0-DC78F78BAB4EQ37801292-EDAD180A-172B-4775-9E7D-32DDBFDA2427Q37820390-73CC8331-AD02-4522-B807-AB35C1F83246Q37827620-C85F744A-8189-47EF-80B8-5291F771768BQ37899907-A1146449-ACE2-4915-85B5-E57C5FA4CEDBQ37910062-6E19D6D6-351B-4211-BFF2-85BAE35AF687Q37918526-03C431DC-DDBD-47C1-A22B-900EF30D59C8Q37939271-4D70BBB0-178B-4BD1-AD2F-0B0D038FDECFQ37980260-8BAC015C-F08D-466E-BABD-A3A566FC75C6Q37990796-BF22801D-8C64-4770-838F-6D866E5C4B78Q37993917-FB129311-610A-49E2-8224-F7363D1412E9Q38068099-93EACB15-459D-4159-A7E3-98B8AB60B793
P2860
Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Renal effects of aliskiren com ...... hypertension, and albuminuria.
@en
Renal effects of aliskiren com ...... hypertension, and albuminuria.
@nl
type
label
Renal effects of aliskiren com ...... hypertension, and albuminuria.
@en
Renal effects of aliskiren com ...... hypertension, and albuminuria.
@nl
prefLabel
Renal effects of aliskiren com ...... hypertension, and albuminuria.
@en
Renal effects of aliskiren com ...... hypertension, and albuminuria.
@nl
P2093
P2860
P50
P921
P356
P1433
P1476
Renal effects of aliskiren com ...... hypertension, and albuminuria.
@en
P2093
A H Jan Danser
Erik Frandsen
Frans Boomsma
Hans-Henrik Parving
Henrik Reinhard
P2860
P304
P356
10.2337/DC09-0168
P407
P577
2009-07-08T00:00:00Z